Centro di Ricerca "E. Menni", Fondazione Poliambulanza- Istituto Ospedaliero, Brescia, Italy.
Centro di Ricerca "E. Menni", Fondazione Poliambulanza- Istituto Ospedaliero, Brescia, Italy.
Placenta. 2017 Nov;59:154-162. doi: 10.1016/j.placenta.2017.05.011. Epub 2017 May 18.
Placenta-derived mesenchymal stromal cells (MSC) have often been considered to linger behind their equivalents from other tissues, such as MSC from bone marrow, in many aspects including their therapeutic potential in regenerative medicine. Nowadays however, it is clear that certain aspects make placental MSC attractive as a cellular therapy, such as their lack of ethical concerns and ease of isolation from human term placenta, a material long regarded as biological waste. Moreover, placental MSC virtually lack expression of human leukocyte antigens and co-stimulatory molecules, making them very attractive for transplantation in allogeneic settings. In the context of cancer, cell therapy remains an area of intense investigation whereby MSC have been shown to play opposing roles, and placental MSC are no exception. In this review, we will discuss dichotomy of placental MSC that underscores the challenges in understanding their therapeutic potential in oncology.
胎盘间充质基质细胞（MSC）在许多方面，如在再生医学中的治疗潜力，往往被认为落后于其他组织来源的 MSC，如骨髓 MSC。然而，如今很明显，某些方面使胎盘 MSC 作为细胞治疗具有吸引力，例如它们不存在伦理问题，并且易于从人类足月胎盘分离，胎盘长期以来被视为生物废物。此外，胎盘 MSC 实际上几乎不表达人类白细胞抗原和共刺激分子，这使它们在同种异体移植中非常有吸引力。在癌症的背景下，细胞治疗仍然是一个深入研究的领域，MSC 已被证明具有相反的作用，胎盘 MSC 也不例外。在这篇综述中，我们将讨论胎盘 MSC 的二分法，这突显了理解其在肿瘤学中的治疗潜力所面临的挑战。
